2026-04-17T04:19:04Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/136892025-09-30T02:07:32Zcom_2072_378070com_2072_378040col_2072_378092

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma BAURAIN, JEAN-FRANCOIS Martelli, Serena Arntz, Ramon Savoia, Paola MUÑOZ COUSELO, EVA Berking, Carola Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris Carcinoma basocel·lular - Tractament DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Basal Cell Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma basocelular Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos Secondary resistance; Locally advanced basal cell carcinoma Resistencia secundaria; Carcinoma basocelular localmente avanzado Resistència secundària; Carcinoma basocel·lular localment avançat The BOLT study was sponsored and funded by Novartis; this analysis was funded by Sun Pharma. Medical writing and editorial support were funded by Sun Pharma Europe B.V. 2025-09-30T02:07:32Z 2025-09-30T02:07:32Z 2025-09-30T02:07:32Z 2025-09-19T08:25:45Z 2025-09-19T08:25:45Z 2025-09 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/13689 Journal of the European Academy of Dermatology and Venereology;39(9) https://doi.org/10.1111/jdv.20629 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess Wiley Scientia